Ajulemic acid

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Ajulemic acid
Ajulemicacid.png
Clinical data
Trade namesAnabasum
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
MetabolismMinimal
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC25H36O4
Molar mass400.56 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Ajulemic acid (AB-III-56, HU-239, IP-751, CPL 7075, CT-3, Anabasum) is a synthetic cannabinoid derivative of the THC metabolite 11-nor-9-carboxy-THC that shows analgesic and anti-inflammatory effects in pre-clinical studies without causing a subjective "high".[1] It is being developed for the treatment of neuropathic pain and inflammatory conditions such as arthritis.[2] It does not share the anti-emetic effects of some other cannabinoids, but may be useful for treating pain and chronic inflammatory conditions where nausea is not present.[3] Side effects include dry mouth, tiredness, and dizziness. The mechanism of action has not yet been fully established, but ajulemic acid may activate the CB2 receptor in the periphery leading to production of resolving eicosanoids. Studies in animals at doses up to 40 mg/kg show minimal psychoactivity of ajulemic acid, comparable to that produced by tetrahydrocannabinol.[4] A composition of ajulemic acid named Anabasum (formerly Resunab) is being developed by Corbus Pharmaceuticals (formerly JB Therapeutics) for the treatment of orphan life-threatening inflammatory diseases.[citation needed]

References[edit]

  1. ^ Burstein, S.; Karst, M.; Schneider, U.; Zurier, R. (2004). "Ajulemic acid: A novel cannabinoid produces analgesia without a "high"". Life Sciences. 75 (12): 1513–1522. doi:10.1016/j.lfs.2004.04.010. PMID 15240185.
  2. ^ Mitchell, V.; Aslan, S.; Safaei, R.; Vaughan, C. (2005). "Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain". Neuroscience Letters. 382 (3): 231–235. doi:10.1016/j.neulet.2005.03.019. PMID 15925096.
  3. ^ Burstein, S. (2005). "Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials". The AAPS Journal. 7 (1): E143–E148. doi:10.1208/aapsj070115. PMC 2751505. PMID 16146336.
  4. ^ Vann, R.; Cook, C.; Martin, B.; Wiley, J. (2007). "Cannabimimetic properties of ajulemic acid". The Journal of Pharmacology and Experimental Therapeutics. 320 (2): 678–686. doi:10.1124/jpet.106.111625. PMC 2633725. PMID 17105826.